

Valentin al Jalali, MD (Dr. med. univ.)

Address: Waehringer Guertel 18-20, 1090 Vienna, Austria
Email: valentin.aljalali@meduniwien.ac.at
Phone: (+43) 1 40 400 29810
ORCID iD: [0000-0002-9196-1936](https://orcid.org/0000-0002-9196-1936)



Education

Doctoral programme of Applied Medical Science at	
Department of Clinical Pharmacology (MUV)	since 10/2017
Studies of Medicine at MUV	10/2008 to 03/2015
• Studies abroad at University of Pretoria, South Africa	10/2012 to 12/2012
High-school diploma at Wöhlerschule Gymnasium, Frankfurt am Main, Germany	09/1998 to 06/2007

Work

Doctor in training for Internal Medicine at Medical University of Vienna (MUV)	since 10/2017
Researcher and Clinical Investigator at Ludwig Boltzmann Institute Applied Diagnostics	since 01/2018
Doctor in training at Wilheminspital (Hospital)	01/2017 to 08/2017
Doctor in training at Otto-Wagner-Spital (Hospital)	10/2016 to 12/2016
Doctor in training at Hartmannspital (Hospital)	05/2015 to 07/2016
Clinical Trial Associate at Boston Children's Hospital (Harvard Medical School)	08/2013
Clinical Trial Associate for J&P Medical Research	01/2012 to 09/2013

Research experience

Independent planning, conduct and analysis of numerous academic phase I-IV studies
Involved as Sub-Investigator in planning and conduct of multiple industry-sponsored phase I-III studies

Grants and funds received

Medical Scientific Fund of the Mayor of the City Vienna (2020)

Reviewer for international journals

Antimicrobial Agents and Chemotherapy (IF 5.9), Journal of Antimicrobial Chemotherapy (IF 5.8), European Journal of Clinical Pharmacology (IF 3.1), Central European Journal of Medicine (IF 2.3)

Memberships of scientific and medical societies

European Society of Clinical Microbiology and Infectious Diseases (ESCMID), PK/PD of Anti-Infectives Study Group of ESCMID (EPASG), International Society of Anti-Infective Pharmacology (ISAP), Austrian Society for Infectious Diseases and Tropical Medicine (ÖGIT)

First-author publications

1. **al Jalali V**, Wasinger G, Rasul S, Grubmueller B, Wulkersdorfer B, Balber T, Mitterhauser M, Simon J, Hacker M, Shariat S, Egger G, Zeitlinger M. *Consecutive PSMA and AR PET imaging shows positive correlation to AR and PSMA protein expression in primary hormone naïve prostate cancer*. J Nucl Med. 2023 Jan 19;jnumed.122.264981. doi: 10.2967/jnumed.122.264981. (IF 11.1)
2. **al Jalali V**, Bauer M, Wölfl-Duchek M, Sarhan M, Wicha SG, Poschner S, Jäger W, König F, Male C, Zeitlinger M. *Pilot Pharmacokinetic Study in Healthy Adults Using Intravascular Microdialysis Catheters Modified for Use in Paediatric Patients to Assess Vancomycin Blood Levels*. Clinical Pharmacokinetics 2022 Dec 6. doi:10.1007/s40262-022-01190-7. (IF 5.6)
3. **al Jalali V**, Scherzer S, Zeitlinger M. *Improved immunogenicity against SARS-CoV-2 in a solid-organ transplant recipient by switching vaccines*. Clinical Microbiology and Infection 2021 Oct 27. doi: 10.1016/j.cmi.2021.06.022 (IF 13.3)
4. **al Jalali V**, Wölfl-Duchek M, Taubert M, Matzneller P, Lackner E, Dorn C, Kratzer A, Wulkersdorfer B, Österreicher Z, Zeitlinger M. *Plasma and soft tissue pharmacokinetics of ceftolozane/tazobactam in healthy volunteers after single and multiple intravenous infusion: a microdialysis study*. Journal of Antimicrobial Chemotherapy 2021 Aug 12. doi: 10.1093/jac/dkab166 (IF 5.8)
5. **al Jalali V**, Matzneller P, Wulkersdorfer B, Chou S, Bahmany S, Koch BCP, Zeitlinger M. *Clinical pharmacokinetics of fosfomycin after continuous infusion compared with intermittent infusion: a randomized crossover study in healthy volunteers*. Antimicrobial Agents and Chemotherapy 2020 Oct 26. doi: 10.1128/AAC.01375-20. (IF 4.9)
6. **al Jalali V**, Zeitlinger M. *Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents*. Clinical Pharmacokinetics 2020 Feb 26. doi: 10.1007/s40262-020-00871-5 (IF 5.6)
7. **al Jalali V**, Sauermann R, Eberl S, Zeitlinger M. *In vitro activity of voriconazole and amphotericin B against Candida albicans, Candida krusei, and Cryptococcus neoformans in human cerebrospinal fluid*. Infection. 2019 Aug;47(4):565-570. doi: 10.1007/s15010-019-01275-9 (IF 7.5)
8. **al Jalali V**, Zeitlinger M. *Clinical Pharmacokinetics and Pharmacodynamics of Telavancin compared with the Other Glycopeptides*. Clinical Pharmacokinetics 2018 Jul;57(7):797-816. doi: 10.1007/s40262-017-0623-4 (IF 5.6)

Co-author publications

1. Sanz-Codina M, Wicha SG, Wulkersdorfer B, **al Jalali V**, Van Os W, Vossen MG, Bauer M, Lackner E, Dorn C, Zeitlinger M. *Comparison of ultrafiltration and microdialysis for ceftriaxone protein-binding determination*. J Antimicrob Chemother. 2022 Nov 26;dkac400. doi: 10.1093/jac/dkac400.
2. Jorda A, Wulkersdorfer B, Schoergenhofer C, Matzneller P, **al Jalali V**, Bauer M, Wölfl-Duchek M, Lackner E, Dorn C, Jilma B, Zeitlinger M. *Effect of the human endotoxin challenge on tedizolid tissue penetration*. Br J Clin Pharmacol. 2022 Oct 12. doi: 10.1111/bcp.15564.
3. Bergmann F, Wulkersdorfer B, Oesterreicher Z, Bauer M, **al Jalali V**, Nussbaumer-Pröll A, Wölfl-Duchek M, Jorda A, Lackner E, Reiter B, Stimpfl T, Ballarini N, König F, Zeitlinger M. *Comparison of pharmacokinetics and stability of generics of cefepime, linezolid and piperacillin/tazobactam with their respective originator drugs: an intravenous bioequivalence study in healthy volunteers*. J Antimicrob Chemother. 2022 Oct 28;77(11):3086-3092. doi: 10.1093/jac/dkac285.
4. Alshaer MH, Barlow B, Maranchick N, Moser M, Gramss L, Burgmann H, **Jalali VA**, Wölfl-Duchek M, Jäger W, Poschner S, Plöchl W, Reinprecht A, Rössler K, Gruber A, Zeitlinger M, Peloquin CA, Hosmann A. *Meropenem Population Pharmacokinetics and Simulations in Plasma, Cerebrospinal Fluid, and Brain Tissue*. Antimicrob Agents Chemother. 2022 Aug 16;66(8):e0043822. doi: 10.1128/aac.00438-22.
5. Büsker S, Jäger W, Poschner S, Mayr L, **al Jalali V**, Gojo J, Azizi AA, Ullah S, Bilal M, El Tabei L, Fuhr U, Peyrl A. *Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors*. Cancer Chemother Pharmacol. 2022 May;89(5):617-627. doi: 10.1007/s00280-022-04424-4.
6. Jorda A, Wulkersdorfer B, Schörgenhofer C, Matzneller P, **al Jalali V**, Bauer M, Wölfl-Duchek M, Lackner E, Dorn C, Jilma B, Zeitlinger M. *Influence of tedizolid on the cytokine response to the endotoxin challenge in healthy volunteers: a cross-over trial*. J Antimicrob Chemother. 2022 Feb 15. doi: 10.1093/jac/dkac039
7. Hosmann A, Ritscher L, Burgmann H, **al Jalali V**, et al. *Meropenem concentrations in brain tissue of neurointensive care patients exceed CSF levels*. J Antimicrob Chemother. 2021 Oct 11. doi: 10.1093/jac/dkab286
8. Edlinger-Stanger M, **al Jalali V**, Andreas M, Jäger W, Böhmendorfer M, Zeitlinger M, Hutschala D. *Plasma and Lung Tissue Pharmacokinetics of Ceftaroline Fosamil in Patients Undergoing Cardiac Surgery with Cardiopulmonary Bypass: an In Vivo Microdialysis Study*. Antimicrob Agents Chemother. 2021 Sep 17. doi: 10.1128/AAC.00679-21
9. Bauer M, Lackner E, Matzneller P, **al Jalali V**, et al. *Phase I Study to Assess Safety of Laser-Assisted Topical Administration of an Anti-TNF Biologic in Patients With Chronic Plaque-Type Psoriasis*. Front Med (Lausanne). 2021 Jul 16. doi: 10.3389/fmed.2021.712511
10. Matzneller P, Oesterreicher Z, Wulkersdorfer B, **al Jalali V**, Mascher D, Mascher H, Zeitlinger M. *Microdialysis as a potential tool for comparative assessment of tissue pharmacokinetics of two different patches containing lidocaine: A crossover pilot study*. Int J Clin Pharmacol Ther. 2021 Jul 8. doi: 10.5414/CP203922
11. Wulkersdorfer B, Wicha SG, Kurdina E, Carrion Carrera SF, Matzneller P, **al Jalali V**, et al. *Protein binding of clindamycin in vivo by means of intravascular microdialysis in healthy volunteers*. J Antimicrob Chemotherapy 2021 May 10. doi: 10.1093/jac/dkab140